Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-J591 in glioblastoma multiforme
NCT02410577Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2015
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Open-label trial of 89Zr-DFO-huJ591 in glioblastoma (GBM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Binding of 89Zr-J591 at 1 year. Started Apr 2015; status: completed.
02
Drugs
89Zr-DFO-huJ591
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02410577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02410577.